Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction
Courtney A Henry, Ronald A Lyon, Hua Ling Department of Pharmacy Practice, School of Pharmacy, Hampton University, Hampton, VA, USA Abstract: Multiple categories of medications have been developed to manage lipid profiles and reduce the risk of cardiovascular events in patients with heart disease....
Main Authors: | Henry CA, Lyon RA, Ling H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-04-01
|
Series: | Vascular Health and Risk Management |
Subjects: | |
Online Access: | https://www.dovepress.com/clinical-efficacy-and-safety-of-evolocumab-for-low-density-lipoprotein-peer-reviewed-article-VHRM |
Similar Items
-
Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016-09-01) -
Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
by: Dixon DL, et al.
Published: (2017-07-01) -
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01) -
Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial
by: Hong Tan, et al.
Published: (2023-02-01) -
A retrospective nationwide analysis of evolocumab use in Sweden and its effect on low-density lipoprotein cholesterol levels
by: Maria K. Svensson, et al.
Published: (2024-01-01)